SCHEMBL14701494

SCHEMBL14701494

CC(C)(C1CCN(C(=O)[C@H](N)Cc2ccccc2)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 5/20 0.55
CYP3A4 P08684 2/20 0.55
NR1I2 O75469 2/20 0.55
OPRD1 P41143 3/20 0.50
DPP4 P27487 2/20 0.47
DPP8 Q6V1X1 2/20 0.47
DPP9 Q86TI2 2/20 0.47
DPP7 Q9UHL4 2/20 0.47
SMYD3 Q9H7B4 1/20 0.46
OPRK1 P41145 2/20 0.45
FAP Q12884 1/20 0.42
AKT1 P31749 1/20 0.42
AKT2 P31751 1/20 0.42
AKT3 Q9Y243 1/20 0.42
F2 P00734 1/20 0.42
KMT2A Q03164 1/20 0.42
HDAC8 Q9BY41 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8048097 1.00 CACNA1B (0.55) CACNA1BCYP3A4NR1I2OPRD1DPP4
Hydrochloric Acid SCHEMBL3041722 0.99 CACNA1B (0.54) CACNA1BCYP3A4NR1I2OPRD1DPP4
Trifluoroacetic Acid SCHEMBL3032929 0.98 CACNA1B (0.54) CACNA1BCYP3A4NR1I2OPRD1DPP4
SCHEMBL13221557 0.95 CACNA1B (0.56) CACNA1BCYP3A4NR1I2OPRD1DPP4
Trifluoroacetic Acid SCHEMBL3032237 0.95 CACNA1B (0.54) CACNA1BCYP3A4NR1I2OPRD1DPP4
Trifluoroacetic Acid SCHEMBL3128776 0.91 CACNA1B (0.47) CACNA1BCYP3A4NR1I2OPRD1DPP4
SCHEMBL3042698 0.90 CACNA1B (0.56) CACNA1BCYP3A4NR1I2SMYD3KMT2A
SCHEMBL3035933 0.90 CACNA1B (0.56) CACNA1BCYP3A4NR1I2SMYD3KMT2A
SCHEMBL3133139 0.90 CACNA1B (0.56) CACNA1BCYP3A4NR1I2SMYD3KMT2A
SCHEMBL3136630 0.86 CACNA1B (0.54) CACNA1BCYP3A4NR1I2OPRK1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205083-B1 Substituted aryl sulfone derivatives as calcium channel blockers MERCK SHARP & DOHME (US) 2013-07-17 EP claimed
US-20130040932-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD. (CA) 2013-02-14 US disclosed
US-20130040932-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD. (CA) 2013-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040932-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CACNA1B 23/4885CYP3A4 939/4885NR1I2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.